1. DOP50 Oral α4β7 integrin inhibitor MORF-057 demonstrates exposure driven biomarker response in non-human primates. (21st January 2022) Authors: Wong, J; Lee, D; Mangada, M; Yadav, V; Troast, D; Zhong, C; Hahn, K; Wang, W; Ge, X; Sun, L; Jiang, S; Wang, B; Zhang, J; Yan, L; Nguyen, H; Cui, D; Bursavich, M G; Lippa, B; Rogers, B N; Ray, A S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i098 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P037 Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion properties of MORF-057 support its clinical development as an oral selective α4β7 integrin inhibitor. (27th May 2021) Authors: Jones, J; Lee, D; Smukste, I; Cui, D; Bursavich, M G; Troast, D; Zhong, C; Wong, J E; Mangada, M M; Bain, G; Lippa, B; Ray, A S; Rogers, B N Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗